Key result
Percutaneous LVADs show no early mortality benefit over IABPs in severe LV dysfunction.
Why the study?
Does a percutaneous left ventricular assist device reduce early mortality compared to an intra-aortic balloon pump in patients with severe left ventricular dysfunction undergoing PCI or VT ablation?
Meta-Analysis (n=688)
Does a percutaneous left ventricular assist device reduce early mortality compared to an intra-aortic balloon pump in patients with severe left ventricular dysfunction undergoing PCI or VT ablation?
In patients with severe LV dysfunction undergoing PCI or VT ablation, PLVAD does not improve early survival compared to IABP and is associated with a higher rate of non-MACCE complications.
PLVAD offers no early mortality benefit over IABP in severe LV dysfunction; reinforces IABP preference while highlighting need for complication-focused RCTs.
Objective Although controversial, the intra‐aortic balloon pump (IABP) and percutaneous left ventricular assist device (PLVAD) are widely used for initial hemodynamic stabilization. We performed a meta‐analysis to compare the clinical outcomes of these two devices in patients with severe left ventricular (LV) dysfunction undergoing percutaneous coronary intervention (PCI) or ventricular tachycardia (VT) ablation. Methods MEDLINE, EMBASE, the Cochrane Registry of Controlled Trials, and reference lists of relevant articles were searched. We included randomized controlled trials (RCTs) and prospective observational studies. Meta‐analysis was conducted using a random effects model. Results The quantitative analysis included 4 RCTs and 2 observational studies. A total of 348 patients received PLVAD and 340 received IABP. Meta‐analysis revealed that early mortality rates (in‐hospital or 30‐day) did not differ between the PLVAD and IABP groups (relative risk ( RR ) = 1.03, 95% confidence interval ( CI ) = 0.70–1.51, P = 0.89). Significant differences were observed between the two groups in the composite, in‐hospital, non‐major adverse cardiac and cerebrovascular events (MACCE) rate ( RR = 1.30, 95% CI = 1.01–1.68, P = 0.04). Conclusions Compared with IABP, PLVAD with active circulatory support did not improve early survival in those with severe left ventricular dysfunction undergoing either PCI or VT ablation, but increased the in‐hospital non‐MACCE rate.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2018) conducted a meta-analysis in Severe left ventricular dysfunction undergoing percutaneous coronary intervention (PCI) or ventricular tachycardia (VT) ablation, or cardiogenic shock (n=688). Percutaneous left ventricular assist device (PLVAD) vs. Intra-aortic balloon pump (IABP) was evaluated on Early mortality (in-hospital or 30-day death) (RR 1.03, 95% CI 0.70-1.51, p=0.89). Percutaneous left ventricular assist devices did not improve early mortality compared to intra-aortic balloon pumps (RR 1.03) in patients with severe left ventricular dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: